Analysis of clinical manifestation and risk factors of chronic obstructive pulmonary disease with hypertension

YAN Xiaopei; SHI Baoyu; WANG Hui; JIN Minghua; XU Xiao; XU Li

doi:10.7619/jcmp.20201154

Journal of Clinical Medicine in Practice > 2021 > 25(3): 63-68. > DOI: 10.7619/jcmp.20201154

YAN Xiaopei, SHI Baoyu, WANG Hui, JIN Minghua, XU Xiao, XU Li. Analysis of clinical manifestation and risk factors of chronic obstructive pulmonary disease with hypertension[J]. Journal of Clinical Medicine in Practice, 2021, 25(3): 63-68. DOI: 10.7619/jcmp.20201154

Citation:

PDF (719 KB)

Analysis of clinical manifestation and risk factors of chronic obstructive pulmonary disease with hypertension

Department of Respiratory and Critical Care Medicine, Suzhou Municipal Hospital in Jiangsu Province, Suzhou Hospital Affiliated to Nanjing Medical University, Suzhou, Jiangsu, 215000

More Information

Received Date: December 20, 2020
Available Online: March 03, 2021
Published Date: March 03, 2021

Graphical Abstract

Abstract

Abstract

Objective To evaluate the prevalence, clinical characteristics, and risk factors of untreated patients with newly diagnosed chronic obstructive pulmonary disease (COPD) with hypertension.
Methods A total of 569 newly diagnosed COPD patients were selected by cross-sectional population screening, and divided into COPD patients with hypertension group (n=249) and COPD patients without hypertension group (n=320). Respiratory symptoms, quality of life score and blood indexes were observed in the two groups; high risk factors of newly diagnosed COPD with hypertension were analyzed.
Results The mean age, male ratio, body mass index (BMI) and smoking index in the COPD with hypertension group were significantly higher than those in the COPD without hypertension group (P < 0.05). The rates of diabetes and cardiovascular disease in the COPD with hypertension group were significantly higher than those in the COPD without hypertension group (P < 0.05). The score of modified medical research council (mMRC) and COPD assessment test (CAT) in the COPD with hypertension group were significantly higher than those in the COPD without hypertension group (P < 0.05). The total white blood cell count, neutrophils count, eosinophils count and monocytes count in the COPD with hypertension group were significantly higher than those in the COPD without hypertension group (P < 0.05). The levels of venous fasting blood glucose, triglyceride, uric acid and serum creatinine in the COPD with hypertension group were significantly higher, and the levels of high-density lipoprotein cholesterol were significantly lower than those in the COPD without hypertension group (P < 0.05). Older age, obesity, elevated fasting blood glucose and absolute monocyte value are independent risk factors for COPD with hypertension.
Conclusion COPD patients with increasing age, obesity, increased monocyte count, and hyperglycemia are more likely to be accompanied by hypertension, and their quality of life is poor. It is of great significance to comprehensively evaluate and monitor the metabolic status of COPD patients, control risk factors and reduce the incidence of complications.
- chronic obstructive pulmonary disease,
- hypertension,
- clinical manifestation,
- risk factor

FullText(HTML)

References (34)

References

[1]	SHEN Y C, CHEN L, WEN F Q. Inter-rotation of 2019 global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease[J]. Zhonghua Yi Xue Za Zhi, 2018, 98(48): 3913-3916. http://www.ncbi.nlm.nih.gov/pubmed/30669793
[2]	ADELOYE D, CHUA S, LEE C, et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis[J]. J Glob Heal, 2015, 5(2): 020415. doi: 10.7189/jogh.05.020415
[3]	WANG C, XU J Y, YANG L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health[CPH] study): a national cross-sectional study[J]. Lancet, 2018, 391(10131): 1706-1717. doi: 10.1016/S0140-6736(18)30841-9
[4]	GREULICH T, WEIST B J D, KOCZULLA A R, et al. Prevalence of comorbidities in COPD patients by disease severity in a German population[J]. Respir Med, 2017, 132: 132-138. doi: 10.1016/j.rmed.2017.10.007
[5]	WANG M T, LIOU J T, LIN C W, et al. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease[J]. JAMA Intern Med, 2018, 178(2): 229. doi: 10.1001/jamainternmed.2017.7720
[6]	Standardization of spirometry, 1994 update. American thoracic society[J]. Am J Respir Crit Care Med, 1995, 152(3): 1107-1136. doi: 10.1164/ajrccm.152.3.7663792
[7]	DIVO M, COTE C, DE TORRES J P, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2012, 186(2): 155-161. doi: 10.1164/rccm.201201-0034OC
[8]	AMARAL A F, PATEL J, GNATIUC L, et al. Association of pulse wave velocity with total lung capacity: a cross-sectional analysis of the BOLD London study[J]. Respir Med, 2015, 109(12): 1569-1575. doi: 10.1016/j.rmed.2015.10.016
[9]	BRUNNER E J, SHIPLEY M J, WITTE D R, et al. Arterial stiffness, physical function, and functional limitation: the Whitehall Ⅱ Study[J]. Hypertension, 2011, 57(5): 1003-1009. doi: 10.1161/HYPERTENSIONAHA.110.168864
[10]	DUPREZ D A, HEARST M O, LUTSEY P L, et al. Associations among lung function, arterial elasticity, and circulating endothelial and inflammation markers: the multiethnic study of atherosclerosis[J]. Hypertension, 2013, 61(2): 542-548. doi: 10.1161/HYPERTENSIONAHA.111.00272
[11]	MIELE C H, GRIGSBY M R, SIDDHARTHAN T, et al. Environmental exposures and systemic hypertension are risk factors for decline in lung function[J]. Thorax, 2018, 73(12): 1120-1127. doi: 10.1136/thoraxjnl-2017-210477
[12]	COLAFELLA K M M, DENTON K M. Sex-specific differences in hypertension and associated cardiovascular disease[J]. Nat Rev Nephrol, 2018, 14(3): 185-201. doi: 10.1038/nrneph.2017.189
[13]	LIN X, WANG X, LI X, et al. Gender-and age-specific differences in the association of hyperuricemia and hypertension: a cross-sectional study[J]. Int J Endocrinol, 2019, 2019: 7545137. http://www.researchgate.net/publication/331418335_Gender-_and_Age-Specific_Differences_in_the_Association_of_Hyperuricemia_and_Hypertension_A_Cross-Sectional_Study
[14]	MANNINO D M, THORN D, SWENSEN A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD[J]. Eur Respir J, 2008, 32(4): 962-969. doi: 10.1183/09031936.00012408
[15]	MERCADO N, ITO K, BARNES P J. Accelerated ageing of the lung in COPD: new concepts[J]. Thorax, 2015, 70(5): 482-489. doi: 10.1136/thoraxjnl-2014-206084
[16]	BUIST A S, MCBURNIE M A, VOLLMER W M, et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study[J]. Lancet, 2007, 370(9589): 741-750. doi: 10.1016/S0140-6736(07)61377-4
[17]	CHATILA W M, THOMASHOW B M, MINAI O A, et al. Comorbidities in chronic obstructive pulmonary disease[J]. Proc Am Thorac Soc, 2008, 5(4): 549-555. doi: 10.1513/pats.200709-148ET
[18]	TSILIGIANNI I G, KOSMAS E, VAN DER MOLEN T, et al. Managing comorbidity in COPD: a difficult task[J]. Curr Drug Targets, 2013, 14(2): 158-176. doi: 10.2174/1389450111314020004
[19]	CORBI G, BIANCO A, TURCHIARELLI V, et al. Potential mechanisms linking atherosclerosis and increased cardiovascular risk in COPD: focus on Sirtuins[J]. Int J Mol Sci, 2013, 14(6): 12696-12713. doi: 10.3390/ijms140612696
[20]	FINKS S W, RUMBAK M J, Self T H. Treating hypertension in chronic obstructive pulmonary disease[J]. N Engl J Med, 2020, 382(4): 353-363. doi: 10.1056/NEJMra1805377
[21]	ZEWARI S, HADI L, VAN DEN ELSHOUT F, et al. Obesity in COPD: comorbidities with practical consequences[J]. COPD, 2018, 15(5): 464-471. doi: 10.1080/15412555.2018.1509951
[22]	LEONE N, COURBON D, THOMAS F, et al. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity[J]. Am J Respir Crit Care Med, 2009, 179(6): 509-516. doi: 10.1164/rccm.200807-1195OC
[23]	DEKKERS B G J, SCHAAFSMA D, TRAN T, et al. Insulin-induced laminin expression promotes a hypercontractile airway smooth muscle phenotype[J]. Am J Respir Cell Mol Biol, 2009, 41(4): 494-504. doi: 10.1165/rcmb.2008-0251OC
[24]	LEE H, KIM S R, OH Y, et al. Targeting insulin-like growth factor-I and insulin-like growth factor-binding protein-3 signaling pathways. A novel therapeutic approach for asthma[J]. Am J Respir Cell Mol Biol, 2014, 50(4): 667-677. doi: 10.1165/rcmb.2013-0397TR
[25]	NIE Z, JACOBY D B, FRYER A D. Hyperinsulinemia potentiates airway responsiveness to parasympathetic nerve stimulation in obese rats[J]. Am J Respir Cell Mol Biol, 2014, 51(2): 251-261. http://europepmc.org/abstract/med/24605871
[26]	LUMENG C N, SALTIEL A R. Inflammatory links between obesity and metabolic disease[J]. J Clin Investig, 2011, 121(6): 2111-2117. doi: 10.1172/JCI57132
[27]	MIRRAKHIMOV A E. Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony[J]. Cardiovasc Diabetol, 2012, 11: 132. doi: 10.1186/1475-2840-11-132
[28]	SPRANGER J, KROKE A, MÖHLIG M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study[J]. Diabetes, 2003, 52(3): 812-817. doi: 10.2337/diabetes.52.3.812
[29]	Barnes P J, Celli B R. Systemic manifestations and comorbidities of COPD[J]. Eur Respir J, 2009, 33(5): 1165-1185. doi: 10.1183/09031936.00128008
[30]	SUN Y T, GONG Y, ZHU R H, et al. Relationship between white blood cells and hypertension in Chinese adults: The Cardiometabolic Risk in Chinese (CRC) study[J]. Clin Exp Hypertens, 2015, 37(7): 594-598. doi: 10.3109/10641963.2015.1036058
[31]	KRISZBACHER I, KOPPÁN M, BÓDIS J. Inflammation, atherosclerosis, and coronary artery disease[J]. N Engl J Med, 2005, 353(4): 429-30; authorreply429-30. doi: 10.1056/NEJM200507283530425
[32]	HAO W D, LI M X, ZHANG Y Q, et al. Expressions of MMP-12, TIMP-4, and neutrophil elastase in PBMCs and exhaled breath condensate in patients with COPD and their relationships with disease severity and acute exacerbations[J]. J Immunol Res, 2019, 2019: 7142438. http://www.onacademic.com/detail/journal_1000042304615599_773d.html
[33]	LLORENTE-CORTÉS V, DE GONZALO-CALVO D, ORBE J, et al. Signature of subclinical femoral artery atherosclerosis in peripheral blood mononuclear cells[J]. Eur J Clin Invest, 2014, 44(6): 539-548. doi: 10.1111/eci.12267
[34]	CHENG S L, LIN C H, WANG C C, et al. Comparison between COPD Assessment Test (CAT) and modified Medical Research Council (mMRC) dyspnea scores for evaluation of clinical symptoms, comorbidities and medical resources utilization in COPD patients[J]. J Formos Med Assoc, 2019, 118(1 pt 3): 429-435. http://www.ncbi.nlm.nih.gov/pubmed/30150099

Cited By

Cited by

Periodical cited type(5)

1.	陈瑞，陈涛，邵俊，叶敬霆，朱继高，唐程斌. 急性A型主动脉夹层合并下肢缺血的处理策略. 实用临床医药杂志. 2023(16): 63-67 . 本站查看
2.	宋艳艳，刘利，李明亮，曲成良，姜博. 体重指数对Stanford A型主动脉夹层术后并发症的影响. 宁夏医学杂志. 2022(01): 35-37 .
3.	宋艳艳，马富珍，李艳婷. 64例Stanford A型主动脉夹层孙氏术后围术期处理. 宁夏医科大学学报. 2020(03): 313-316 .
4.	陈国锋，牛冬梅，王国锋，杨学超，王青青，汪高磊. 内膜片旷置法主动脉根部成形在Standford A型夹层中的应用. 中国循证心血管医学杂志. 2019(06): 733-735 .
5.	林曦，谢强丽，陈蓓蓓，曹艳君，刘庆华，金枝. 心脏主动脉夹层术后医院感染相关因素分析及预防对策研究. 中华医院感染学杂志. 2018(13): 1975-1978 .

Other cited types(1)

Get Citation

PDF

XML

Article views (298) PDF downloads (23) Cited by(6)

Turn off MathJax

Article Contents

Abstract

References

Analysis of clinical manifestation and risk factors of chronic obstructive pulmonary disease with hypertension

Abstract

References

Cited by

Periodical cited type(5)

Other cited types(1)

Catalog

Export File

Citation

Format

Content